184 related articles for article (PubMed ID: 37031047)
1. Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review.
Le BK; McGarrah P; Paciorek A; Mohamed A; Apolo AB; Chan DL; Reidy-Lagunes D; Hauser H; Rivero JD; Whitman J; Batty K; Zhang L; Raj N; Le T; Bergsland E; Halfdanarson TR
Clin Genitourin Cancer; 2023 Jun; 21(3):403-414.e5. PubMed ID: 37031047
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological Spectrum of Primary and Metastatic Neuroendocrine Neoplasms.
Hashmi AA; Ali J; Khan K; Ahmed O; Rehman AU; Irfan M; Haroon S; Asif MG
Cureus; 2020 Nov; 12(11):e11764. PubMed ID: 33409012
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological Features of Primary Neuroendocrine Tumors of Gastrointestinal/Pancreatobiliary Tract With Emphasis on High-Grade (Grade 3) Well-Differentiated Neuroendocrine Tumors.
Hashmi AA; Ali J; Yaqeen SR; Ahmed O; Asghar IA; Irfan M; Asif MG; Edhi MM; Hashmi S
Cureus; 2021 Jan; 13(1):e12640. PubMed ID: 33585126
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Analysis of Presacral Neuroendocrine Neoplasms-Clinicopathological Characterization and Treatment Outcomes of a Rare Disease.
Matrood S; Apostolidis L; Schrader J; Krug S; Lahner H; Ramaswamy A; Librizzi D; Kender Z; Kröcher A; Kreutzfeldt S; Gress TM; Rinke A
Front Endocrinol (Lausanne); 2021; 12():709256. PubMed ID: 34690926
[TBL] [Abstract][Full Text] [Related]
5. Tumor Macroscopic Morphology Is an Important Prognostic Factor in Predicting Chemotherapeutic Efficacy and Clinical Outcomes of Patients With Colorectal Neuroendocrine Neoplasms, One Multicenter Retrospective Cohort Study.
Wang Z; An K; Li R; Liu Q
Front Endocrinol (Lausanne); 2021; 12():801741. PubMed ID: 34987482
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
Chan DL; Bergsland EK; Chan JA; Gadgil R; Halfdanarson TR; Hornbacker K; Kelly V; Kunz PL; McGarrah PW; Raj NP; Reidy DL; Thawer A; Whitman J; Wu L; Becker C; Singh S
Oncologist; 2021 Nov; 26(11):950-955. PubMed ID: 34342086
[TBL] [Abstract][Full Text] [Related]
7. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
8. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
9. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry.
Bellizzi AM
Adv Anat Pathol; 2013 Sep; 20(5):285-314. PubMed ID: 23939147
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms.
Waseem N; Aparici CM; Kunz PL
J Nucl Med; 2019 Jul; 60(7):882-891. PubMed ID: 30850504
[TBL] [Abstract][Full Text] [Related]
11. The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases.
Kapacee ZA; Allison J; Dawod M; Wang X; Frizziero M; Chakrabarty B; Manoharan P; McBain C; Mansoor W; Lamarca A; Hubner R; Valle JW; McNamara MG
Curr Oncol; 2022 Jul; 29(7):5110-5125. PubMed ID: 35877265
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake.
Ostwal V; Basu S; Bhargava P; Shah M; Parghane RV; Srinivas S; Chaudhari V; Bhandare MS; Shrikhande SV; Ramaswamy A
Neuroendocrinology; 2021; 111(10):998-1004. PubMed ID: 33017827
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
14. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.
Thang SP; Lung MS; Kong G; Hofman MS; Callahan J; Michael M; Hicks RJ
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):262-277. PubMed ID: 28894897
[TBL] [Abstract][Full Text] [Related]
15. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.
Pusceddu S; Prinzi N; Tafuto S; Ibrahim T; Filice A; Brizzi MP; Panzuto F; Baldari S; Grana CM; Campana D; Davì MV; Giuffrida D; Zatelli MC; Partelli S; Razzore P; Marconcini R; Massironi S; Gelsomino F; Faggiano A; Giannetta E; Bajetta E; Grimaldi F; Cives M; Cirillo F; Perfetti V; Corti F; Ricci C; Giacomelli L; Porcu L; Di Maio M; Seregni E; Maccauro M; Lastoria S; Bongiovanni A; Versari A; Persano I; Rinzivillo M; Pignata SA; Rocca PA; Lamberti G; Cingarlini S; Puliafito I; Ambrosio MR; Zanata I; Bracigliano A; Severi S; Spada F; Andreasi V; Modica R; Scalorbi F; Milione M; Sabella G; Coppa J; Casadei R; Di Bartolomeo M; Falconi M; de Braud F
JAMA Netw Open; 2022 Feb; 5(2):e220290. PubMed ID: 35201309
[TBL] [Abstract][Full Text] [Related]
16. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours.
Hoskoppal D; Epstein JI; Gown AM; Arnold Egloff SA; Gordetsky JB; Shi CJ; Giannico GA
Histopathology; 2020 Mar; 76(4):550-559. PubMed ID: 31595536
[TBL] [Abstract][Full Text] [Related]
17. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.
Chan DL; Rodriguez-Freixinos V; Doherty M; Wasson K; Iscoe N; Raskin W; Hallet J; Myrehaug S; Law C; Thawer A; Nguyen K; Singh S
Eur J Cancer; 2022 Jul; 169():74-81. PubMed ID: 35504244
[TBL] [Abstract][Full Text] [Related]
18. Single institutional experience on primary neuroendocrine neoplasms of the kidney: a rare distinct entity.
Amin M; Trikalinos N; Chatterjee D
Hum Pathol; 2021 Aug; 114():36-43. PubMed ID: 33891968
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Metastatic Patterns Among Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Nonneuroendocrine Carcinomas of Various Primary Organs.
Park HK; Kwon GY
J Korean Med Sci; 2023 Mar; 38(11):e85. PubMed ID: 36942393
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
Puliafito I; Chillari F; Russo A; Cantale O; Sciacca D; Castorina L; Colarossi C; Franchina T; Vitale MP; Ricciardi GRR; Adamo V; Esposito F; Giuffrida D
Front Endocrinol (Lausanne); 2023; 14():1065599. PubMed ID: 36793289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
